News

13 May 2016

Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins

Proteon Therapeutics Inc., a collaborator of Biopta, today announced publication of additional nonclinical data on Vonapanitase, an investigational drug under development to improve Arteriovenous Fistula (AVF) maturation and patency in chronic kidney disease patients.
Read More >>

21 Apr 2016

Proteon and Biopta publication shows promising nonclinical results on Proteon's Vonapanitase

Proteon Therapeutics Inc. a collaborator of Biopta, today announced publication of additional nonclinical data on investigational drug vonapanitase in peripheral artery disease (PAD).
Read More >>

25 Nov 2015

Biopta to be acquired by Japanese stem cell company ReproCELL

Biopta is to be acquired by the stem cell and regenerative medicine company ReproCELL. The deal will help Biopta to expands its range of drug discovery services based on human fresh tissues.
Read More >>

18 Nov 2015

Biopta co-authors research in the European Respiratory Journal

The impact of fresh human tissue studies for translational work performed at Biopta has once again been demonstrated with this latest publication at the European Respiratory Society.
Read More >>

1 2 3 4 >>

Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins

13/05/2016

Proteon Therapeutics Announces Publication in Cardiovascular Pharmacology: Open Access Describing Promising Nonclinical Results for Vonapanitase in Improving Arteriovenous Fistula (AVF) Maturation and patency in Chronic Kidney Disease (CKD) Patients.

Proteon Therapeutics Inc. (Nasdaq:PRTO), a longstanding client of Biopta, is developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. Proteon today announced publication of additional nonclinical data on investigational drug vonapanitase in chronic kidney disease (CKD). The ex vivo study demonstrated that  vonapanitase removed elastic fibres from human cephalic veins in a dose-dependent manner, as assessed by both desmosine and histological staining of elastic fibres.
 
The study, titled Recombinant Human Elastase Treatment of Cephalic Veins, was published in Cardiovascular Pharmacology: Open Access. Proteons Senior Vice President and Chief Medical Officer, Steven Burke, M.D., is the senior author of the published manuscript. Dr Karen Bingham and Dr Emma Moss of Biopta were co-authors. The full paper can be accessed here

Live chat by BoldChat